You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,703,800


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,703,800
Title:Cell culture medium
Abstract: Provided herein, inter alia, are compositions and methods for culturing mammalian cells. In certain aspects, the composition is a medium containing one or more of a lithium ion source, one or more fatty acids, and/or ethanol. Use of any of the cell culture media described herein to culture cells that have been genetically engineered to produce one or more recombinant polypeptides (for example, antibodies) can result in increased titers, a more favorable glycosylation profile, and/or modulated (e.g. decreased) amounts of high and low molecular weight species, and/or modulated (e.g. decreased) amounts of acidic or basic charge variants, compared to cells cultured in a medium that does not contain one or more of a lithium ion source, one or more fatty acids, and/or ethanol.
Inventor(s): Leber; Christopher T. (San Diego, CA), Shen; Michael W.Y. (San Diego, CA), Tao; Yiwen (San Diego, CA), Murray, IV; Hugh Eugene (San Diego, CA)
Assignee: LA JOLLA BIOLOGICS, INC. (San Diego, CA)
Application Number:15/498,221
Patent Claims:1. A method for producing one or more recombinant polypeptides from an engineered mammalian cell, the method comprising: (a) culturing said engineered mammalian cell in a medium under suitable conditions for the production of said one or more recombinant polypeptides, and increasing the concentration of lithium ions in the medium during the culturing; and (b) producing said one or more recombinant polypeptides, wherein the medium comprises (i) a basal medium or a feed medium; and (ii) one or more sources of lithium ions.

2. The method of claim 1, wherein the method further comprises (c) isolating said one or more recombinant polypeptides.

3. The method of claim 1, wherein the medium is (a) a basal medium; or (b) a feed medium.

4. The method of claim 1 wherein said one or more recombinant polypeptides is an antibody or fragment thereof.

5. The method of claim 4, wherein said antibody is a monoclonal antibody.

6. The method of claim 5, wherein the monoclonal antibody inhibits the growth of a proliferating cell.

7. The method of claim 4, wherein said antibody or fragment thereof binds to HER2, TNF-.alpha., VEGF-A, .alpha.4-integrin, CD20, CD52, CD25, CD11a, EGFR, respiratory syncytial virus (RSV), glycoprotein IIb/IIIa, IgG1, IgE, complement component 5 (C5), B-cell activating factor (BAFF), CD19, CD30, interleukin-1 beta (IL1.beta.), prostate specific membrane antigen (PSMA), CD38, RANKL, GD2, SLAMF7 (CD319), proprotein convertase subtilisin/kexin type 9 (PCSK9), dabigatran, cytotoxic T-lymphocyte-associated protein 4 (CTLA4), interleukin-5 (IL-5), programmed cell death protein (PD-1), VEGFR2 (KDR), protective antigen (PA) of B. anthracis, interleukin-17 (IL-17), interleukin-6 (IL-6), interleukin-6 receptor (IL6R), interleukin-12 (IL-12), interleukin 23 (IL-23), sclerostin (SOST), myostatin (GDF-8), activin receptor-like kinase 1, delta like ligand 4 (DLL4), angiopoietin 3, VEGFR1, selectin, oxidized low-density lipoprotein (oxLDL), platelet-derived growth factor receptor beta, neuropilin 1, Von Willebrand factor (vWF), integrin .alpha..sub.v.beta..sub.3, neural apoptosis-regulated proteinase 1, integrin .alpha..sub.11b.beta..sub.3, beta-amyloid, reticulon 4 (RTN4)/Neurite Outgrowth Inhibitor (NOGO-A), nerve growth factor (NGF), LINGO-1, myelin-associated glycoprotein, or integrin .alpha.4.beta.7.

8. The method of claim 5, wherein said monoclonal antibody is trastuzumab, pertuzumab, infliximab, adalimumab, bevacizumab, ranibizumab, natalizumab, rituximab, alemtuzumab, daclizumab, efalizumab, golimumab, certolizumab, cetuximab, panitumumab, palivizumab, abciximab, basiliximab, ibritumomab, omalizumab, eculizumab, abciximab, alirocumab, basiliximab, belimumab, blinatumomab, brentuximab, canakinumab, capromab, daratumumab, denosumab, dinutuximab, eculizumab, elotuzumab, evolocumab, idarucizumab, ipilimumab, mepolizumab, necitumumab, nivolumab, obinutuzumab, ofatumumab, palivizumab, pembrolizumab, ramucirumab, raxibacumab, ecukinumab, siltuximab, tocilizumab, ustekinumab, alacizumab, denosumab, blosozumab, romosozumab, stamulumab, alirocumab, ascrinvacumab, enoticumab, evinacumab, evolocumab, icrucumab, inclacumab, nesvacumab, orticumab, ramucirumab, rinucumab, vesencumab, bococizumab, caplacizumab, demcizumab, etaracizumab, idarucizumab, ralpancizumab, tadocizumab, aducanumab, atinumab, fasinumab, fulranumab, gantenerumab, opicinumab, bapineuzumab, crenezumab, ozanezumab, ponezumab, refanezumab, solanezumab, tanezumab, and vedolizumab.

9. A method for modulating the glycosylation profile of one or more recombinant polypeptides produced by a genetically engineered mammalian cell, the method comprising: (a) culturing said mammalian cell in a medium under suitable conditions for the production of said one or more recombinant polypeptides, and increasing the concentration of lithium ions in the medium during the culturing; and (b) producing said one or more recombinant polypeptides, wherein the medium comprises (i) a basal medium or a feed medium; and (ii) one or more sources of lithium ions, and wherein said one or more recombinant polypeptides has a modulated glycosylation profile compared to recombinant polypeptides produced by mammalian cells that are not cultured in the medium.

10. The method of claim 9, wherein said modulated glycosylation profile comprises modulated terminal mannose glycan species.

11. The method of claim 9, wherein said modulated glycosylation comprises modulation of one or more glycan species selected from mannose-5-N-acetylglycosamine-2 (Man5), mannose-6-N-acetylglycosamine-2 (Man6), mannose-3-N-acetylglucosamine-4 (G0), mannose-3-N-acetylglucosamine-4-fucose (G0F), mannose-3-N-acetylglucosamine-4-galactose-1-fucose (G1F), and/or mannose-3-N-acetylglucosamine-4-galactose-2-fucose (G2F).

12. The method of claim 9, wherein the ratio of the terminal mannose glycan species to the total sum of glycan species is modulated by about 40% to about 50%.

13. The method of claim 9, wherein said one or more recombinant polypeptides is an antibody or fragment thereof.

14. The method of claim 13, wherein said antibody is a monoclonal antibody.

15. The method of claim 14, wherein the monoclonal antibody inhibits the growth of a proliferating cell.

16. The method of claim 13, wherein said antibody or fragment thereof binds to HER2, TNF-.alpha., VEGF-A, .alpha.4-integrin, CD20, CD52, CD25, CD11a, EGFR, respiratory syncytial virus (RSV), glycoprotein IIb/IIIa, IgG1, IgE, complement component 5 (C5), B-cell activating factor (BAFF), CD19, CD30, interleukin-1 beta (IL1.beta.), prostate specific membrane antigen (PSMA), CD38, RANKL, GD2, SLAMF7 (CD319), proprotein convertase subtilisin/kexin type 9 (PCSK9), dabigatran, cytotoxic T-lymphocyte-associated protein 4 (CTLA4), interleukin-5 (IL-5), programmed cell death protein (PD-1), VEGFR2 (KDR), protective antigen (PA) of B. anthracis, interleukin-17 (IL-17), interleukin-6 (IL-6), interleukin-6 receptor (IL6R), interleukin-12 (IL-12), interleukin 23 (IL-23), sclerostin (SOST), myostatin (GDF-8), activin receptor-like kinase 1, delta like ligand 4 (DLL4), angiopoietin 3, VEGFR1, selectin, oxidized low-density lipoprotein (oxLDL), platelet-derived growth factor receptor beta, neuropilin 1, Von Willebrand factor (vWF), integrin .alpha..sub.v.beta..sub.3, neural apoptosis-regulated proteinase 1, integrin .alpha..sub.11b.beta..sub.3, beta-amyloid, reticulon 4 (RTN4)/Neurite Outgrowth Inhibitor (NOGO-A), nerve growth factor (NGF), LINGO-1, myelin-associated glycoprotein, or integrin .alpha.4.beta.7.

17. The method of claim 14, wherein said monoclonal antibody is trastuzumab, pertuzumab, infliximab, adalimumab, bevacizumab, ranibizumab, natalizumab, rituximab, alemtuzumab, daclizumab, efalizumab, golimumab, certolizumab, cetuximab, panitumumab, palivizumab, abciximab, basiliximab, ibritumomab, omalizumab, eculizumab, abciximab, alirocumab, basiliximab, belimumab, blinatumomab, brentuximab, canakinumab, capromab, daratumumab, denosumab, dinutuximab, eculizumab, elotuzumab, evolocumab, idarucizumab, ipilimumab, mepolizumab, necitumumab, nivolumab, obinutuzumab, ofatumumab, palivizumab, pembrolizumab, ramucirumab, raxibacumab, ecukinumab, siltuximab, tocilizumab, ustekinumab, alacizumab, denosumab, blosozumab, romosozumab, stamulumab, alirocumab, ascrinvacumab, enoticumab, evinacumab, evolocumab, icrucumab, inclacumab, nesvacumab, orticumab, ramucirumab, rinucumab, vesencumab, bococizumab, caplacizumab, demcizumab, etaracizumab, idarucizumab, ralpancizumab, tadocizumab, aducanumab, atinumab, fasinumab, fulranumab, gantenerumab, opicinumab, bapineuzumab, crenezumab, ozanezumab, ponezumab, refanezumab, solanezumab, tanezumab, and vedolizumab.

18. The method of claim 1, wherein the medium further comprises (c) ethanol; and/or (d) one or more fatty acids.

19. The method of claim 18, wherein said one or more fatty acids is selected from the group consisting of oleic acid, linoleic acid, linolenic acid, myristic acid, palmitic acid stearic acid, thymol, cholesteryl acetate, methyl octanoate, 1-octanoyl-rac-glycerol, cholesterol, butyric (C4), valeric (C5), caproic (C6), enanthic (C7), caprylic (C8), pelargonic (C9), capric (C10), undecylic (C11), lauric (C12), tridecylic (C13), myristic (C14), pentadecanoic (C15), margaric (C17), nonadecylic (C19), arachidic (C20), heneicosylic (C21), behenic (C22), tricosylic (C23), lignoceric (C24), pentacosylic (C25), cerotic (C26), heptacosylic (C27), montanic (C28), nonacosylic (C29), melissic (C30), hentriacontylic (C31), lacceroic (C32), psyllic (C33), geddic (C34), ceroplastic (C35), hexatriacontylic (C36), heptatriacontanoic (C37), and octatriacontanoic (C38) acids.

20. The method of claim 1, wherein said one or more sources of lithium ions is selected from the group of one or more of lithium acetate, lithium chloride, lithium carbonate, lithium oxybutyrate, lithium orotate, lithium bromide, lithium citrate, lithium fluoride, lithium iodide, lithium nitrate, and lithium sulfate.

21. The method of claim 1, wherein said lithium ions are present in a concentration from about 0.1 .mu.M to about 25 mM.

22. The method of claim 1, wherein the concentration of lithium ions in the medium is increased daily by about 0.1 mM to about 1.11 mM.

23. The method of claim 22, wherein the concentration of lithium ions in the medium is increased daily by about 0.1 mM, about 0.11 mM, about 0.5 mM, about 0.44 mM, about 1 mM, or about 1.11 mM.

24. The method of claim 9, wherein the concentration of lithium ions in the medium is increased daily by about 0.1 mM to about 1.11 mM.

25. The method of claim 24, wherein the concentration of lithium ions in the medium is increased daily by about 0.1 mM, about 0.11 mM, about 0.5 mM, about 0.44 mM, about 1 mM, or about 1.11 mM.

Details for Patent 10,703,800

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 12/22/1994 ⤷  Try a Trial 2036-04-26
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2036-04-26
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 12/10/1997 ⤷  Try a Trial 2036-04-26
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 05/12/1998 ⤷  Try a Trial 2036-04-26
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 01/02/2003 ⤷  Try a Trial 2036-04-26
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab For Injection 103770 06/19/1998 ⤷  Try a Trial 2036-04-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.